Cover Image
市場調查報告書

REGiMMUNE Corporation:產品平台分析

REGiMMUNE Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253779
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
REGiMMUNE Corporation:產品平台分析 REGiMMUNE Corporation - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 25 Pages
簡介

REGiMMUNE Corporation是開發治療免疫疾病用解決方案的生物科技企業。

本報告提供REGiMMUNE Corporation的產品開發平台現狀及各開發階段比較分析,提供您藥物簡介,開發平台的分析與最新趨勢,暫停中的計劃等資訊。

REGiMMUNE Corporation的基本資料

REGiMMUNE Corporation概要

  • 主要資訊
  • 企業資料

REGiMMUNE Corporation:R&D概要

  • 主要的治療範圍

REGiMMUNE Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

REGiMMUNE Corporation:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

REGiMMUNE Corporation:藥物簡介

  • RGI-2001
  • RGI-1001
  • RGI-3100
  • RGI-5000
  • RGI-4000系列

REGiMMUNE Corporation:開發平台分析

  • 各給藥途徑
  • 各分子類型

REGiMMUNE Corporation:最近的開發平台趨勢

REGiMMUNE Corporation:暫停中的計劃

REGiMMUNE Corporation:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07317CDB

Summary

Global Markets Direct's, 'REGiMMUNE Corporation - Product Pipeline Review - 2015', provides an overview of the REGiMMUNE Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of REGiMMUNE Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of REGiMMUNE Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of REGiMMUNE Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the REGiMMUNE Corporation's pipeline products

Reasons to buy

  • Evaluate REGiMMUNE Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of REGiMMUNE Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the REGiMMUNE Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of REGiMMUNE Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of REGiMMUNE Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of REGiMMUNE Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • REGiMMUNE Corporation Snapshot
    • REGiMMUNE Corporation Overview
    • Key Information
    • Key Facts
  • REGiMMUNE Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • REGiMMUNE Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • REGiMMUNE Corporation - Pipeline Products Glance
    • REGiMMUNE Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • REGiMMUNE Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • REGiMMUNE Corporation - Drug Profiles
    • RGI-2001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGI-1001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGI-3100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGI-5000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGI-4000 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • REGiMMUNE Corporation - Pipeline Analysis
    • REGiMMUNE Corporation - Pipeline Products by Route of Administration
    • REGiMMUNE Corporation - Pipeline Products by Molecule Type
  • REGiMMUNE Corporation - Recent Pipeline Updates
  • REGiMMUNE Corporation - Dormant Projects
  • REGiMMUNE Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • REGiMMUNE Corporation, Key Information
  • REGiMMUNE Corporation, Key Facts
  • REGiMMUNE Corporation - Pipeline by Indication, 2015
  • REGiMMUNE Corporation - Pipeline by Stage of Development, 2015
  • REGiMMUNE Corporation - Monotherapy Products in Pipeline, 2015
  • REGiMMUNE Corporation - Phase II, 2015
  • REGiMMUNE Corporation - Preclinical, 2015
  • REGiMMUNE Corporation - Discovery, 2015
  • REGiMMUNE Corporation - Pipeline by Route of Administration, 2015
  • REGiMMUNE Corporation - Pipeline by Molecule Type, 2015
  • REGiMMUNE Corporation - Recent Pipeline Updates, 2015
  • REGiMMUNE Corporation - Dormant Developmental Projects,2015
  • REGiMMUNE Corporation, Other Locations

List of Figures

  • REGiMMUNE Corporation - Pipeline by Top 10 Indication, 2015
  • REGiMMUNE Corporation - Pipeline by Stage of Development, 2015
  • REGiMMUNE Corporation - Monotherapy Products in Pipeline, 2015
  • REGiMMUNE Corporation - Pipeline by Top 10 Molecule Type, 2015
Back to Top